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Previewsto produce BAFF, APRIL, and CXCL13 as
well as molecules that enable TGF-b
synthesis that together control IgA secre-
tion in MALT (Suzuki et al., 2010). It would
therefore be interesting to determine
whether follicular DCs are also involved
in this relay by recruiting activated
pDCs to B cell follicles to regulate IgA
production.
By demonstrating a major role for
MALT-resident pDCs, rather than cDCs,
in regulating TI IgA responses under
steady-state conditions, these findings
(Tezuka et al., 2011) add another layer
of complexity to the regulation of mu-
cosal IgA responses. In light of other
studies (Jego et al., 2003; Massacand
et al., 2008; Mora et al., 2006; Sato et al.,
2003; Suzuki et al., 2010; Tezuka et al.,
2007; Uematsu et al., 2008), it is clear
that induction of IgA by DCs differentially
depends on TGF-b, IL-6, RA, BAFF, and
APRIL, with the requirement for each of
these factors reflecting the nature of the
DC subset, the inflammatory or quiescent
milieu, the availability of T cell help, and
the specific location within the MALT
(Figure 1). These findings also raise
several interesting questions. First, it
remains unclear why IgA responses in
PP were predominantly TD whereas
those in the MLN were TI despite the146 Immunity 34, February 25, 2011 ª2011 Efact that pDCs and stromal cells isolated
from these sites appeared to be function-
ally similar with respect to expression of
elevated amounts of BAFF and APRIL
and type I IFNs, respectively, compared
to corresponding cells in non-MALT sites
(i.e., spleen, PLN). Second, it is unknown
whether BAFF, APRIL, or BAFF-APRIL
heterodimers or a combination of these
molecules is the key mediator of pDC-
induced IgA secretion. And lastly, the
receptor expressed on B cells that
delivers the BAFF and APRIL signal for
CSR to IgA in this setting remains to be
identified. Although TACI has been impli-
cated in IgA production in vitro (Cerutti
et al., 2010; Tangye et al., 2006), it will
be important to establish whether this
also occurs within MALT and whether
an impairment in this pathway contrib-
utes to the Ig deficiency in humans with
mutations in TNFRSF13B (encoding
TACI). Although this study by Tezuka
et al. (2011) has shed substantial light
on the dynamic control of IgA production,
answers to these questions will pro-
vide a greater understanding of the
biology of IgA-mediated immunity during
TD and TI responses and potentially
reveal strategies for improving such
responses in healthy and immunodefi-
cient individuals.lsevier Inc.REFERENCES
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Most successful vaccines elicit antibodies that protect against infection. In this issue of Immunity, Bomsel
et al. (2011) show in the rhesus macaque model that vaccine-induced mucosal antibodies, rather than circu-
lating neutralizing antibodies, may be critical components for protective immunity against HIV-1.Antibodies patrolling the mucosal epithe-
lium can play a crucial role in blocking
HIV-1entryand infectionafter sexual expo-
sure. Bomsel et al. (2011), in this issue of
Immunity, report that an HIV-1 gp41 enve-
lope vaccine elicits mucosal antibodies in
rhesusmacaques thatmay protect againstsimian-human chimeric immunodeficiency
virus (SHIV) infection after repeated intra-
vaginal low-dose exposures (Bomsel
et al., 2011). Protected animals mounted
vaginal IgA antibodies, which blocked
HIV-1 transcytosis, and IgG antibodies,
which mediated antibody-dependentcellular cytotoxicity (ADCC). However, the
animals lacked serum neutralizing anti-
bodies. These findings highlight the contri-
bution of diverse effector activities of anti-
bodies in defending against HIV-1 at the
portal of entry and raise the question of
whether circulating, broadly reactive
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Figure 1. HIV-1 Gp41 Subunit Virosome Vaccine Study Eliciting Protection against Intravaginal SHIV
The vaccine contained a recombinant truncated trimeric gp41 spanning HIV-1 HXB2 residues 540–663 (excluding 593–618) and a P1 peptide spanning residues
649–683, each formulated in influenza virosomes. Four injections were given at weeks 0, 7, 15, and 23. Group 1 (n = 6) received four vaccine doses intramus-
cularly, group 2 received two vaccine doses IM followed by two vaccine doses intranasally, and group 3 received four doses of empty virosome IM as the placebo
control. One month after vaccination, animals were challenged intravaginally 13 times with SHIVSF152P3. Vaccine-induced protection against sustained infection
was observed in three of six recipients in group 1 and five of five recipients in group 2; all placebo recipients became infected over the 6 months of follow up.
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Previewsneutralizing antibodies are essential
components of immunity needed to
prevent HIV-1 acquisition by vaccination.
For more than two decades, the ‘‘holy
grail’’ for HIV-1 vaccine research has
been the development of an immunogen
that elicits antibodies that neutralize
a wide range of HIV-1 strains. Sadly, all
vaccines advanced to date have failed to
potently induce such antibodies. Their
absence is largely believed to account
for failed efficacy of the two prototype
recombinant gp120 bivalent vaccines.
Major challenges lie in the ability to
construct a stable immunogen that reveals
conservedenvelope-neutralizingepitopes
that appear antigenically different from
self proteins and that are not obscured
by immunodominant nonneutralizing or
variable epitopes (Mascola and Monte-
fiori, 2010; McElrath and Haynes, 2010;
Walker and Burton, 2010). Moreover,
should such an immunogen be found, an
additional hurdle lies in targeting the re-
sulting neutralizing antibodies to the
mucosa. A vaccine strategy that demon-
strates high efficacy yet circumvents any
of these challenges would be welcome.
Rather than using the conventional
gp120 surface protein vaccine, Bomselet al. (2011) took a unique approach.
They constructed two antigens from the
ectodomain of HIV-1HXB2 gp41 trans-
membrane protein: (1) a truncated
trimeric gp41 excluding nonneutralizing,
immunodominant epitopes and (2)
a lipid-linked P1 peptide spanning the
extended membrane proximal external
region (MPER). These antigens were
inserted into the lipid membrane of
virosomes and delivered either in four
doses intramuscularly (IM) or in two doses
IM followed by two doses intranasally (IN)
(Figure 1). After 1 month, the SHIV
challenge was administered intravaginally
in thirteen 20–30 TCID50 doses over
65 days. After challenge, all six control
animals had sustained or intermittent
peaks of viremia (106–107 copies/mL)
and SIV Gag p27 antibodies. By contrast,
50% of the IM vaccine group had tran-
sient (n = 2) or undetectable (n = 1)
viremia, and all five animals in the mixed
IM+IN group showed either low-level
transient or undetectable viremia. Thus,
the vaccine regimen prevented SHIV
acquisition and/or sustained infection in
8 of 11 vaccinated animals.
What is the significance of these results
and how can they inform new vaccineImmunity 34,development? The first consideration is
the utility of the nonhuman primate (NHP)
model in predicting clinical efficacy of
HIV-1 vaccines in humans. Large viral
inocula, historically used inNHPchallenge
models, can override the immunity
a vaccine affords, making it difficult to
identify vaccine-induced correlates of
protection. Here, the authors employed
a repeated low-dose mucosal challenge
with a CCR5—using SHIV to reliably
capture features of mucosal HIV-1 trans-
mission and to evaluate the effects of
envelope antibodies. Although a sample
size of 25 animals per arm has been esti-
mated tobesufficient toobserveavaccine
effect in this model (Hudgens et al., 2009),
the results here provide a promising lead
for innovative vaccine candidates that
can be validated in larger studies. In addi-
tion, the key immunogenicity findings and
degree of protection in the mixed IM+IN
vaccine arm were greater than in the IM
vaccine arm; the improved genital
mucosal immunitywith intranasal immuni-
zation merits further examination.
Although circulating HIV-1 antibodies
were found in most vaccinated animals,
they were incapable of neutralizing
a representative virus panel or ofFebruary 25, 2011 ª2011 Elsevier Inc. 147
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Previewsmediating ADCC. To understand the
immune components that may have
contributed to vaccine protection, the
investigators appropriately focused on
mucosal IgG and IgA antibody responses.
Surprisingly, low-titer IgG-mediated
ADCC and IgA-mediated transcytosis-
blocking activities that were not observed
in serum of the vaccine-protected animals
were found in cervicovaginal washes.
Moreover, neutralizing antibody response
rates and titers were low to undetectable.
With a broader view, consider these
results compared to the outcome of the
RV144 phase III clinical trial, in which
31.2% efficacy was observed in a rela-
tively low-risk exposed Thai population
(Rerks-Ngarm et al., 2009). In earlier clin-
ical trials, this regimen induced serum
neutralizing antibodies recognizing the
vaccine strain in 71% of vaccinees, but
they were not broadly neutralizing and
unlikely to potently neutralize circulating
strains. Thus, if antibodies were the
main contributors of immune protection,
the effector functions mediating this
outcome may correlate with mucosal
antibody activities. These functions,
largely Fc-mediated effector responses,
may include trapping and aggregating
virus and virus-infected cells in the
mucosa, inhibition of transcytosis,
enhanced macrophage phagocytosis,
and ADCC (reviewed in McElrath and
Haynes, 2010), similar to activities
induced by the immunogen in the Bomsel
et al. study. Clearly, more detailed exam-
ination of mucosal antibody functions is
needed to confirm these findings.
What steps are needed to further eluci-
date and induce immune functions essen-
tial for blocking HIV-1 transmission? First,
assays that can reliably measure the rele-
vant responses are essential. One neutral-
ization assay may be insufficient to detect
the types and functions of vaccine-
induced antibodies. Antibodies that inhibit
HIV-1 replication in macrophages and
dendritic cells may be important for
protection; such functions are unlikely to
be identified by conventional assays using
PBMCorCD4+ T cell lines. Although some
studies have associated protection with
high percentages of viral transcytosis inhi-
bition by vaccine-induced antibodies, it is
important to identify the transcytosis effi-
ciency of the virus(es) in the absence of
antibodies to understand the relevance
of these findings. In addition, IgA148 Immunity 34, February 25, 2011 ª2011 Eantibodies may block transcytosis in
columnar epithelium, such as in the endo-
cervix and rectum, but not in stratified
squamous epithelium found in foreskin
and vagina, areas also vulnerable to
HIV-1. Antibody avidity may also be key
to these interactions and has been shown
to inversely correlate with postchallenge
plasma SHIV titers in at least one NHP
vaccine study (Zhao et al., 2009).
Although mucosal antibodies may be
the most important contributor to protec-
tion in this NHP study, Env-specific T cells
also may have played a role, as the
authors concede, but T cell responses
were not measured. CD4+ T cell helper
responses were probably induced with
the gp41 immunogen, and their activation
and cytokine secretion can promote
downstream IgA B cell differentiation.
Thus, an understanding of the functional
phenotype of vaccine-induced CD4+
T cells and their effector functions in the
mucosa could be gained from the NHP
model. Finally, Env-specific CD8+ T cells
were unlikely to have been primed
through the endogenous MHC class I
pathway, but these could have been
induced by cross-priming activities.
What promise does this immunogen
hold among the portfolio of HIV-1 enve-
lope-based vaccine candidates and
approaches? Safety in humans is unlikely
to be a concern. The virosome formulation
will probably induce mucosal antibodies,
particularly if administered mucosally.
The immunogen epitopes are likely to be
antigenic, given that gp41 IgG antibodies
are commonly found in patients during
acute and chronic HIV-1 infection, as
well as anti-gp41 IgA in highly exposed,
uninfected individuals (Tudor et al.,
2009). By excluding gp41 immunodomi-
nant epitopes, immune responses may
preferentially focus on regions that
enhance antiviral blocking, such as those
shown to mediate ADCC and other
Fc-mediated antiviral activities. It is
unclear whether gp41 immunogens can
be constructed with current technologies
that capture the prehairpin intermediate
conformation that triggers potent neutral-
izing activities similar to the 4E10 and
2F5 monoclonal antibodies that target
the linear epitopes in the MPER region
(McElrath and Haynes, 2010). Frey
and colleagues have recently elucidated
the three distinct conformational states
of gp41 that antibodies recognizelsevier Inc.(Frey et al., 2010), and presumably the
nonneutralizing vaccine-induced anti-
bodies will recognize the post-fusion
conformation. Additional information
about the gp41 trimeric structure and
stability will be necessary tomake conclu-
sive determinations.
These findings underscore two impor-
tant messages for the vaccine field: anti-
body-mediated protection may occur in
the absence of neutralization in serum as
detected by conventional methods, and
examination of immune responses in the
circulation alone may fail to identify key
effector responses that the vaccine
induces. The study raises questions of
whether vaccine-induced nonneutralizing
antibodies play a protective role when
HIV-1 exposure is low-level and whether
this approach can be combined with other
modalities that induceantiviralCD8+Tcells
for greater efficacy. These questions are
feasible to address in future studies.
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